Francois Habersetzer

Summary

Country: France

Publications

  1. pmc Boceprevir and personalized medicine in hepatitis C virus infection
    Francois Habersetzer
    Pôle Hépato Digestif, Hopitaux Universitaires de Strasbourg
    Pharmgenomics Pers Med 5:125-37. 2012
  2. doi request reprint Synthetic anti-lipopolysaccharide peptides and hepatitis C virus infection
    Francois Habersetzer
    Inserm U1110, Institut de Virologie, 3 Rue Koeberle, 67000 Strasbourg, France
    Expert Opin Investig Drugs 22:853-62. 2013
  3. doi request reprint A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C
    Francois Habersetzer
    INSERM, Strasbourg, France Université de Strasbourg, Strasbourg, France
    Gastroenterology 141:890-899.e1-4. 2011
  4. doi request reprint Hepatitis C virus vaccines--progress and perspectives
    Catherine Fauvelle
    INSERM, U1110, Institut de Virologie, Strasbourg, France Université de Strasbourg, Strasbourg, France
    Microb Pathog 58:66-72. 2013
  5. pmc Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C
    Fei Xiao
    INSERM, U1110, Strasbourg, France Université de Strasbourg, Strasbourg, France
    Gut 64:483-94. 2015
  6. pmc Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents
    Fei Xiao
    INSERM, U1110, Strasbourg, France Université de Strasbourg, Strasbourg, France
    PLoS Pathog 10:e1004128. 2014
  7. doi request reprint Challenges for HCV vaccine development in HIV-HCV coinfection
    Mélanie Lambotin
    INSERM, U748, 67000 Strasbourg, France
    Expert Rev Vaccines 11:791-804. 2012
  8. doi request reprint Apolipoprotein E Mediates Evasion From Hepatitis C Virus Neutralizing Antibodies
    Catherine Fauvelle
    INSERM, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France Université de Strasbourg, Strasbourg, France
    Gastroenterology 150:206-217.e4. 2016
  9. pmc Adaptive immunity to hepatitis C virus
    Mirjam B Zeisel
    INSERM, U748, 3 Rue Koeberle, F 67000 Strasbourg, France E Mails M B Z S F K E R F H T F B
    Viruses 1:276-97. 2009
  10. pmc Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment-naive patients
    Rebecca Pastor
    Institut de Virologie, 3 Rue Koeberle, 67000 Strasbourg, France
    World J Gastroenterol 15:753-5. 2009

Collaborators

Detail Information

Publications15

  1. pmc Boceprevir and personalized medicine in hepatitis C virus infection
    Francois Habersetzer
    Pôle Hépato Digestif, Hopitaux Universitaires de Strasbourg
    Pharmgenomics Pers Med 5:125-37. 2012
    ..This review focuses on the main results obtained so far, their impact on the treatment of patients with chronic hepatitis C, and potential therapeutic perspectives...
  2. doi request reprint Synthetic anti-lipopolysaccharide peptides and hepatitis C virus infection
    Francois Habersetzer
    Inserm U1110, Institut de Virologie, 3 Rue Koeberle, 67000 Strasbourg, France
    Expert Opin Investig Drugs 22:853-62. 2013
    ..Although antiviral therapy has been markedly improved by the licensing of direct-acting antivirals, safety, resistance, high costs and difficult-to-treat patients remain important challenges...
  3. doi request reprint A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C
    Francois Habersetzer
    INSERM, Strasbourg, France Université de Strasbourg, Strasbourg, France
    Gastroenterology 141:890-899.e1-4. 2011
    ..We performed a phase I clinical trial to assess the safety, immunogenicity, and early antiviral efficacy of TG4040 in patients with CHC...
  4. doi request reprint Hepatitis C virus vaccines--progress and perspectives
    Catherine Fauvelle
    INSERM, U1110, Institut de Virologie, Strasbourg, France Université de Strasbourg, Strasbourg, France
    Microb Pathog 58:66-72. 2013
    ....
  5. pmc Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C
    Fei Xiao
    INSERM, U1110, Strasbourg, France Université de Strasbourg, Strasbourg, France
    Gut 64:483-94. 2015
    ..Viral entry is a promising target for antiviral therapy...
  6. pmc Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents
    Fei Xiao
    INSERM, U1110, Strasbourg, France Université de Strasbourg, Strasbourg, France
    PLoS Pathog 10:e1004128. 2014
    ..Blocking virus cell-cell transmission prevents emergence of drug resistance in persistent viral infection including resistance to HCV DAAs. ..
  7. doi request reprint Challenges for HCV vaccine development in HIV-HCV coinfection
    Mélanie Lambotin
    INSERM, U748, 67000 Strasbourg, France
    Expert Rev Vaccines 11:791-804. 2012
    ..Here, the authors review the pathogenesis of hepatitis C in HIV-infected patients, with a focus on the impact of HIV on HCV-specific immune responses and discuss the challenges for vaccine development in HIV-HCV coinfection...
  8. doi request reprint Apolipoprotein E Mediates Evasion From Hepatitis C Virus Neutralizing Antibodies
    Catherine Fauvelle
    INSERM, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France Université de Strasbourg, Strasbourg, France
    Gastroenterology 150:206-217.e4. 2016
    ..Lipoprotein association has also been proposed to mediate viral evasion of the humoral immune response, though the mechanisms are poorly defined...
  9. pmc Adaptive immunity to hepatitis C virus
    Mirjam B Zeisel
    INSERM, U748, 3 Rue Koeberle, F 67000 Strasbourg, France E Mails M B Z S F K E R F H T F B
    Viruses 1:276-97. 2009
    ..Unravelling these important mechanisms of virus-host interaction will contribute to the development of novel strategies to prevent and control HCV infection...
  10. pmc Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment-naive patients
    Rebecca Pastor
    Institut de Virologie, 3 Rue Koeberle, 67000 Strasbourg, France
    World J Gastroenterol 15:753-5. 2009
    ..Thus, mutations in untreated patients deserve cautious surveillance. These data indicate that mutations that can theoretically confer adefovir or tenofovir resistance may emerge in treatment-naive patients...
  11. doi request reprint Loss of hepatitis B surface antigen in a real-life clinical cohort of patients with chronic hepatitis B virus infection
    Francois Habersetzer
    Service d Hepatogastroenterologie, Hopitaux Universitaires de Strasbourg, Nouvel Hopital Civil, Strasbourg, F 67091, France Université de Strasbourg, Strasbourg, F 67000, France Unité Inserm 1110, Strasbourg, F 67000, France
    Liver Int 35:130-9. 2015
    ..We sought to identify the parameters associated with HBsAg loss in a well-characterized real-life clinical cohort of chronically HBV-infected patients...
  12. ncbi request reprint GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection
    Francois Habersetzer
    Hopitaux Universitaires de Strasbourg, Service d Hepatogastroenterologie, Strasbourg, France
    Curr Opin Mol Ther 11:456-62. 2009
    ....
  13. doi request reprint Acute hepatitis C virus infection induces anti-host cell receptor antibodies with virus-neutralizing properties
    Rajiv G Tawar
    INSERM, U1110, Institut des Maladies Virales et Hépatiques, Strasbourg, France
    Hepatology 62:726-36. 2015
    ..Functional studies using immunoadsorption and HCV cell culture models demonstrate that HCV-neutralizing anti-receptor Abs are induced in the early phase of HCV infection, but not in control groups...
  14. doi request reprint Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies
    Isabel Fofana
    INSERM, U748, Hopitaux Universitaires de Strasbourg, Strasbourg, France
    Gastroenterology 143:223-233.e9. 2012
    ..We used acute infection of liver graft as a model to investigate the molecular mechanisms of viral evasion...
  15. doi request reprint A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses
    Eloi R Verrier
    INSERM, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France
    Hepatology 63:35-48. 2016
    ..Using a targeted RNA interference entry screen, we identified glypican 5 as a common host cell entry factor for hepatitis B and delta viruses...